Antithymocyte globulin induction therapy improves survival in lung transplantation for cystic fibrosis

Transplant International

Volumn 26, Issue 1, 2013, Pages 34-41

  Jaksch, Peter ^a   Wiedemann, Dominik ^a   Augustin, Victoria ^a   Muraközy, Gabriela ^a   Scheed, Axel ^a   Kocher, Alfred A ^a   Klepetko, Walter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

cystic fibrosis; induction therapy; lung transplantation; rejection; survival

Indexed keywords

ATG FRESENIUS; CYCLOSPORIN A; GANCICLOVIR; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; TRIMETHOPRIM; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ARTICLE; CYSTIC FIBROSIS; DRUG MEGADOSE; FOLLOW UP; HUMAN; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEROID THERAPY; SURVIVAL;

ADULT; BRONCHIOLITIS OBLITERANS; CYSTIC FIBROSIS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HUMANS; LUNG TRANSPLANTATION; MALE;

EID: 84871288531     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01570.x     Document Type: Article

References (20)

1. Lynch 3rd JP, Saggar R, Weigt SS, Ross DJ, Belperio JA,. Overview of lung transplantation and criteria for selection of candidates. Semin Respir Crit Care Med 2006; 27: 441.
2. Braun AT, Merlo CA,. Cystic fibrosis lung transplantation. Curr Opin Pulm Med 2011; 17: 467.
3. Christie JD, Edwards LB, Kucheryavaya AY, etal. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report-2011. J Heart Lung Transplant 2011; 30: 1104.
4. Hopkins PM, McNeil K,. Evidence for immunosuppression in lung transplantation. Curr Opin Organ Transplant 2008; 13: 477.
5. Bhorade SM, Stern E,. Immunosuppression for lung transplantation. Proc Am Thorac Soc 2009; 6: 47.
6. Griffith BP, Hardesty RL, Armitage JM, etal. Acute rejection of lung allografts with various immunosuppressive protocols. Ann Thorac Surg 1992; 54: 846.
7. Palmer SM, Miralles AP, Lawrence CM, Gaynor JW, Davis RD, Tapson VF,. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest 1999; 116: 127.
8. Garrity Jr ER, Villanueva J, Bhorade SM, Husain AN, Vigneswaran WT,. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 2001; 71: 773.
9. Charpentier B, Rostaing L, Berthoux F, etal. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003; 75: 844.
10. Duvoux C, Pageaux GP, Vanlemmens C, etal. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002; 74: 1103.
11. Stewart S, Fishbein MC, Snell GI, etal. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229.
12. Hachem RR, Chakinala MM, Yusen RD, etal. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation. J Heart Lung Transplant 2005; 24: 1320.
13. Brodlie M, Corris PA, Lordan J, Ward C,. Interleukin-17 and cystic fibrosis lung disease. Am J Respir Crit Care Med 2012; 185: 108; author reply 9-10.
14. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC,. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011; 184: 252.
15. Knoop C, Estenne M,. Chronic allograft dysfunction. Clin Chest Med 2011; 32: 311.
16. Patel N, Snyder LD, Finlen-Copeland A, Palmer SM,. Is prevention the best treatment? CMV after lung transplantation. Am J Transplant 2012; 12: 539.
17. Snydman DR, Limaye AP, Potena L, Zamora MR,. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc 2011; 43: S1.
18. Hadjiliadis D,. Special considerations for patients with cystic fibrosis undergoing lung transplantation. Chest 2007; 131: 1224.
19. Dharnidharka VR,. Post-transplant lymphoproliferative disease: association with induction therapy? Drugs 2006; 66: 429.
20. Dharnidharka VR, Stevens G,. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant 2005; 9: 622.